Publications by authors named "Jarmila Simova"

BACKGROUND Histiocytic sarcoma is a rare malignant hematopoietic neoplasm with morphologic and immunohistochemical features of histiocytic differentiation, usually with unfavorable prognosis. Despite aggressive biological behavior, in subgroup of patients with localized disease, the prognosis can be very good. Few publications are available on localized cases of histiocytic sarcoma.

View Article and Find Full Text PDF

The presence of wild-type RAS alleles, as determined by genotyping codons 12, 13, 59, 61, 117, and 146, is a prerequisite for personalized anti-EGFR treatment of metastatic colorectal cancer (mCRC) patients. Here we describe analytical validation of in-house developed massively parallel sequencing technology (MPS) in comparison to the in vitro diagnostics (IVD) certified qPCR method. DNA extracted from FFPE samples from CRC patients (n=703) and reference standards (n=33) were tested for KRAS and NRAS mutations in 6 codons of exons 2, 3, and 4 using deep amplicon sequencing (DAS) on a MiSeq benchtop sequencer (Illumina).

View Article and Find Full Text PDF

Objective: The diagnosis of Bartonella henselae by polymerase chain reaction (PCR) in lymph nodes removed in 10 patients with serologically confirmed evidence cat-scratch disease.

Material And Methods: The 2015-2018 group consisted of 10 patients with serologically confirmed cat-scratch disease, all of them having positive IgG antibodies and 6 patients also positive IgM antibodies against B. henselae.

View Article and Find Full Text PDF

Mutations in IDH1/2 genes are a marker of good prognosis for glioma patients, associated with low grade gliomas and secondary glioblastomas. Immunohistochemistry and Sanger sequencing are current standards for IDH1/2 genotyping while many other methods exist. The aim of this study was to validate Competitive amplification of differentially melting amplicons (CADMA) PCR for IDH genotyping by comparison with SNaPshot assay and two immunohistochemical methods.

View Article and Find Full Text PDF
Article Synopsis
  • Crohn's disease is a complex inflammatory condition primarily affecting the gastrointestinal tract, with genetic factors, particularly mutations in the NOD2/CARD15 gene, believed to play a role in disease expression.
  • A study analyzed 70 Crohn's patients to see if specific gene mutations (R702W, G908R, 3020insC) were linked to the disease's clinical characteristics, finding that 32% had at least one mutation.
  • Results showed no significant differences in disease traits between those with or without mutations, though homozygotes for 3020insC were identified as a high-risk group, suggesting the mutations don't notably affect disease phenotype or reoperation rates.
View Article and Find Full Text PDF

Aims: A germline SNP (rs61764370) is located in a let-7 complementary site (LCS6) in the 3'UTR of KRAS oncogene, and it was found to alter the binding capability of the mature let-7 microRNA to the KRAS mRNA. The aim of the study was to evaluate the frequency of the KRAS-LCS6 variant allele in different cancer types that included patients with colorectal cancer (CRC), breast cancer (BC), non-small cell lung cancer (NSCLC) and brain tumour patient subgroups from the Czech Republic. The occurrence of this genetic variant was correlated with the presence of selected somatic mutations representing predictive biomarkers in the respective tumours.

View Article and Find Full Text PDF

Crohn's disease is often purely inflammatory, but most patients develop complicated disease with strictures or fistulae. Specific etiopathogenesis of this severe disease is not definitely clear despite research efforts and learning of many pathogenetic mechanisms. Many studies have suggested that NOD2 mutations are associated with increased risk of complicated disease.

View Article and Find Full Text PDF
Article Synopsis
  • Targeted therapy is crucial for treating malignant tumors, especially colorectal cancer, using monoclonal anti-EGFR antibodies like cetuximab and panitumumab.
  • Activating mutations in the KRAS gene, specifically in codons 12 and 13, predict poor responses to anti-EGFR therapies in metastatic colorectal cancer patients.
  • In the Czech Republic, laboratories test KRAS mutations, with 60.2% of cases exhibiting non-mutated KRAS, and proper testing procedures are essential for patient stratification and adherence to professional guidelines.*
View Article and Find Full Text PDF